Company Focus
Lonza
Latest Lonza News
Biotechnology
Swiss CDMO Lonza has acquired rights to Nona Biosciences’ transferrin receptor (TfR1) blood-brain barrier technology and expanded its strategic collaboration with the Chinese biotech company. 2 July 2026
Cell & Gene Therapy News
Insights
Company Spotlight
A Cambridge, Massachusetts-based gene-editing company whose CRISPR/Cas9 platform has now delivered the first positive Phase III data for an in vivo gene-editing therapy, with a BLA filed for lonvoguran ziclumeran in hereditary angioedema.
Latest News & Features of interest to Lonza
Biotechnology
Cambridge, UK-based human cell programming company bit.bio today announced the launch of two new cell culture media kits designed to make human cell-based research significantly more accessible and affordable for laboratories worldwide. 6 July 2026
Biotechnology
Swiss CDMO Lonza has acquired rights to Nona Biosciences’ transferrin receptor (TfR1) blood-brain barrier technology and expanded its strategic collaboration with the Chinese biotech company. 2 July 2026
Biotechnology
Novartis today announced that the European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. 2 July 2026
Biotechnology
Hong Kong-listed Chinese biotech METiS TechBio has licensed global rights to its preclinical trispecific T-cell engager MTS-128 to Deerfield-backed Boulevard Bio, in a deal potentially worth more than $1.6 billion plus royalties. 1 July 2026
Biotechnology
Swiss contract development and manufacturing group Lonza today announced an expanded strategic collaboration with a leading, unnamed, USA-based biopharmaceutical company. 1 July 2026
Biotechnology
Privately-held US cell therapy company Orca Bio announced the US Food and Drug Administration (FDA) has approved Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq), clinically known as Orca-T. 1 July 2026
Biotechnology
US biotech Regenxbio has completed dosing in the confirmatory part of its AFFINITY DUCHENNE trial of RGX-202, keeping the company on course for a planned biologics license application (BLA) submission to the US Food and Drug Administration (FDA) in the third quarter of 2026. 25 June 2026
Biotechnology
Shares in US gene therapy developer Regenxbio closed 16.3% higher Monday after the company said it had reached alignment with the US Food and Drug Administration (FDA) on a route to resubmit its biologics license application (BLA) for Navsunli (clemidsogene lanparvovec-sngl), an investigational treatment for mucopolysaccharidosis type II (MPS II), or Hunter syndrome. 23 June 2026
Biotechnology
China-based biotech CARsgen Therapeutics’ shares rose 6.8% to HK$16.82, after it announced that the National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of satricabtagene autoleucel (satri-cel), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy product. 23 June 2026
Biotechnology
US genetic medicines biotech Scribe Therapeutics has secured more than $25 million from the California Institute for Regenerative Medicine to advance two preclinical cardiometabolic programs toward clinical development. 19 June 2026
Latest In Brief for Lonza
Biotechnology
UK biotech Semarion has secured $3.8 million (£2.9 million) to expand manufacturing and commercial reach of its cell-based screening technology, as it moves to convert early pharma interest into broader adoption. 31 March 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze